UNIGE document Scientific Article
previous document  unige:86913  next document
add to browser collection

Adapting Preclinical Benchmarks for First-in-Human Trials of Human Embryonic Stem Cell-Based Therapies

Published in Stem cells translational medicine. 2016, vol. 5, no. 8, p. 1058-66
Abstract : As research on human embryonic stem cell (hESC)-based therapies is moving from the laboratory to the clinic, there is an urgent need to assess when it can be ethically justified to make the step from preclinical studies to the first protocols involving human subjects. We examined existing regulatory frameworks stating preclinical requirements relevant to the move to first-in-human (FIH) trials and assessed how they may be applied in the context of hESC-based interventions to best protect research participants. Our findings show that some preclinical benchmarks require rethinking (i.e., identity, purity), while others need to be specified (i.e., potency, viability), owing to the distinctive dynamic heterogeneity of hESC-based products, which increases uncertainty and persistence of safety risks and allows for limited predictions of effects in vivo. Rethinking or adaptation of how to apply preclinical benchmarks in specific cases will be required repeatedly for different hESC-based products. This process would benefit from mutual learning if researchers included these components in the description of their methods in publications.
PMID: 27334488
Full text
Article (Published version) (672 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group Ethique biomédicale (783)
(ISO format)
BARAZZETTI, Gaia, HURST, Samia, MAURON, Alex. Adapting Preclinical Benchmarks for First-in-Human Trials of Human Embryonic Stem Cell-Based Therapies. In: Stem cells translational medicine, 2016, vol. 5, n° 8, p. 1058-66. doi: 10.5966/sctm.2015-0222 https://archive-ouverte.unige.ch/unige:86913

496 hits

1 download


Deposited on : 2016-09-12

Export document
Format :
Citation style :